-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21

Benzinga·11/13/2026 16:02:19
Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.